Q-omics provides the consensus-scored ZFAND3 profile across patient tissues and cancer cell-line models. ZFAND3 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, ZFAND3 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, ZFAND3 RNA expression shows 19,679 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight SCLC, HNSC, and ACC as cancer lineages where ZFAND3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZFAND3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZFAND3 survival associations across molecular data types. ZFAND3 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZFAND3 RNA expression–survival associations across cancer types. High ZFAND3 expression shows unfavorable associations in ACC, SARC, ESCA and LUSC, but favorable associations in SCLC and KIRC. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for ZFAND3 RNA expression.
This table summarizes ZFAND3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ZFAND3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZFAND3 shows lower tumor expression in THCA and higher tumor expression in HNSC, LIHC, BRCA, CHOL and LUSC. The HNSC box plot shows higher ZFAND3 RNA expression in tumor versus normal tissue (log2 FC = +0.737, t-test p < 0.001).
This table shows molecular features associated with ZFAND3 in patient tissues and cancer cell lines. In patient samples, ZFAND3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZFAND3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
